36. Breast Cancer Res. 2018 Apr 17;20(1):28. doi: 10.1186/s13058-018-0951-9.Morphology and genomic hallmarks of breast tumours developed by ATM deleteriousvariant carriers.Renault AL(1)(2)(3)(4), Mebirouk N(1)(2)(3)(4), Fuhrmann L(5), Bataillon G(5),Cavaciuti E(1)(2)(3)(4), Le Gal D(1)(2)(3)(4), Girard E(1)(2)(3)(4), PopovaT(2)(3)(6), La Rosa P(1)(2)(3)(4), Beauvallet J(1)(2)(3)(4), Eon-MarchaisS(1)(2)(3)(4), Dondon MG(1)(2)(3)(4), d'Enghien CD(7), Laugé A(7), Chemlali W(8),Raynal V(9), Labbé M(1)(2)(3)(4), Bièche I(8), Baulande S(9), Bay JO(10), BerthetP(11), Caron O(12), Buecher B(7), Faivre L(13)(14), Fresnay M(15),Gauthier-Villars M(7), Gesta P(16), Janin N(17), Lejeune S(18), MaugardC(19)(20), Moutton S(21), Venat-Bouvet L(22), Zattara H(23), Fricker JP(24),Gladieff L(25), Coupier I(26)(27); CoF-AT; GENESIS; kConFab, Chenevix-TrenchG(28), Hall J(29)(30)(31), Vincent-Salomon A(5), Stoppa-Lyonnet D(6)(7)(32),Andrieu N(1)(2)(3)(4), Lesueur F(33)(34)(35)(36).Author information: (1)INSERM, U900, Paris, France.(2)Institut Curie, Paris, France.(3)Mines Paris Tech, Fontainebleau, France.(4)PSL Research University, Paris, France.(5)Service de Pathologie, Institut Curie, Paris, France.(6)INSERM U830, Paris, France.(7)Service de Génétique, Institut Curie, Paris, France.(8)Unité de Pharmacogénomique, Institut Curie, Paris, France.(9)Institut Curie Genomics of Excellence (ICGex) Platform, Institut Curie, Paris,France.(10)CHU Estaing, CHU Clermont-Ferrand, Clermont-Ferrand, France.(11)Unité de Pathologie Gynécologique, Centre François Baclesse, Caen, France.(12)Service d'Oncologie Génétique, Gustave Roussy, Villejuif, France.(13)Institut GIMI, CHU de Dijon, Hôpital d'Enfants, Dijon, France.(14)Oncogénétique, Centre de Lutte contre le Cancer Georges François Leclerc,Dijon, France.(15)Département d'Hématologie et d'Oncologie Médicale, CLCC Antoine Lacassagne,Nice, France.(16)Service d'Oncogénétique Régional Poitou-Charentes, Centre HospitalierGeorges-Renon, Niort, France.(17)Service de Génétique, Clinique Universitaire Saint-Luc, Brussels, Belgium.(18)Service de Génétique Clinique Guy Fontaine, Hôpital Jeanne de Flandre, Lille,France.(19)Laboratoire de Diagnostic Génétique, UF1422 Oncogénétique Moléculaire,Hôpitaux Universitaires de Strasbourg, Strasbourg, France.(20)Oncogénétique Evaluation familiale et suivi, UF6948 Oncogénétique, HôpitauxUniversitaires de Strasbourg, Strasbourg, France.(21)Laboratoire Maladies Rares: Génétique et Métabolisme, CHU de Bordeaux-GHPellegrin, Bordeaux, France.(22)Service d'Oncologie Médicale, Hôpital Universitaire Dupuytren, Limoges,France.(23)Département de Génétique, Hôpital de la Timone, Marseille, France.(24)Unité d'Oncogénétique, Centre Paul Strauss, Strasbourg, France.(25)IUCT Oncopole, Institut Claudius Regaud, Toulouse, France.(26)Service de Génétique Médicale et Oncogénétique, Hôpital Arnaud de Villeneuve,CHU de Montpellier, Montpellier, France.(27)Unité d'Oncogénétique, ICM Val d'Aurelle, Montpellier, France.(28)Department of Genetics and Computational Biology, QIMR Berghofer MedicalResearch Institute, Brisbane, Australia.(29)UMR INSERM 1052, Lyon, France.(30)CNRS 5286, Lyon, France.(31)Centre de Recherche en Cancérologie de Lyon, Lyon, France.(32)Université Paris Descartes, Paris, France.(33)INSERM, U900, Paris, France. fabienne.lesueur@curie.fr.(34)Institut Curie, Paris, France. fabienne.lesueur@curie.fr.(35)Mines Paris Tech, Fontainebleau, France. fabienne.lesueur@curie.fr.(36)PSL Research University, Paris, France. fabienne.lesueur@curie.fr.BACKGROUND: The ataxia telangiectasia mutated (ATM) gene is a moderate-riskbreast cancer susceptibility gene; germline loss-of-function variants are foundin up to 3% of hereditary breast and ovarian cancer (HBOC) families who undergogenetic testing. So far, no clear histopathological and molecular features ofbreast tumours occurring in ATM deleterious variant carriers have been described,but identification of an ATM-associated tumour signature may help in patientmanagement.METHODS: To characterise hallmarks of ATM-associated tumours, we performedsystematic pathology review of tumours from 21 participants fromataxia-telangiectasia families and 18 participants from HBOC families, as well ascopy number profiling on a subset of 23 tumours. Morphology of ATM-associatedtumours was compared with that of 599 patients with no BRCA1 and BRCA2 mutations from a hospital-based series, as well as with data from The Cancer Genome Atlas. Absolute copy number and loss of heterozygosity (LOH) profiles were obtained fromthe OncoScan SNP array. In addition, we performed whole-genome sequencing on fourtumours from ATM loss-of-function variant carriers with available frozenmaterial.RESULTS: We found that ATM-associated tumours belong mostly to the luminal Bsubtype, are tetraploid and show LOH at the ATM locus at 11q22-23. Unlike tumoursin which BRCA1 or BRCA2 is inactivated, tumours arising in ATM deleteriousvariant carriers are not associated with increased large-scale genomicinstability as measured by the large-scale state transitions signature. Losses at13q14.11-q14.3, 17p13.2-p12, 21p11.2-p11.1 and 22q11.23 were observed. Somaticalterations at these loci may therefore represent biomarkers for ATM testing and harbour driver mutations in potentially 'druggable' genes that would allowpatients to be directed towards tailored therapeutic strategies.CONCLUSIONS: Although ATM is involved in the DNA damage response, ATM-associated tumours are distinct from BRCA1-associated tumours in terms of morphologicalcharacteristics and genomic alterations, and they are also distinguishable fromsporadic breast tumours, thus opening up the possibility to identify ATM variant carriers outside the ataxia-telangiectasia disorder and direct them towardseffective cancer risk management and therapeutic strategies.DOI: 10.1186/s13058-018-0951-9 PMCID: PMC5905168PMID: 29665859 